January 29, 2026 · Phase 3 readout
NVS Phase 3 readout: a positive outcome, +0.5%
+0.5%Novartis AG (NVS) →
On January 29, 2026, Secukinumab 300 mg, s.c. — Novartis AG (Giant Cell Arteritis) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +0.5% in the window around the event. It had already run +10.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$147.87
1d before
$148.91
Event day
$148.68
1d after
$149.86
5d after
Pre-catalyst setup
+10.2%
30-day run-up
1946%
30-day volatility
1.2×
volume spike